-

A Practical Guide to Producing and Maintaining the Pharmacovigilance System Master File (PSMF) Training Course (VIRTUAL EVENT: Feb 13, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "A Practical Guide to Producing and Maintaining the PSMF Training Course (Feb 13, 2026)" training has been added to ResearchAndMarkets.com's offering.

This course will provide a practical guide to planning, writing, maintaining and updating the PSMF to ensure compliance.

The pharmacovigilance system master file (PSMF) is a legal requirement for any medicinal product authorised in the European Union. The PSMF provides the regulators with a detailed description and assessment of the entire pharmacovigilance system and the outputs contained in the annexes provide an understanding of a company's compliance.

The programme will cover the importance of the PSMF in regulatory inspections, including common PSMF inspection findings. You will discuss the processes and systems required to manage the PSMF as well as the latest advice on the impact of Brexit.

Benefits of attending:

  • Understand the regulatory requirements for the PSMF
  • Gain an overview of the key issues in producing, maintaining and updating the PSMF
  • Discuss the PSMF as a QMS document
  • Learn about the roles of the QPPV and the PSMF
  • Review common inspection findings and deficiencies related to the PSMF

Certification:

  • CPD: 6 hours for your records
  • Certificate of completion

Who Should Attend:

This course will be relevant for anyone working in pharmacovigilance who requires a comprehensive overview of the PSMF, including QPPVs and those responsible for safety assessments. It will also be of interest to those who work with pharmacovigilance, eg in regulatory affairs, clinical, sales and marketing, legal, commercial and quality, as well as the audit group.

Key Topics Covered:

Introduction, welcome and objectives

Introduction and background to the PSMF

  • The DDPS and the PSMF
  • Objectives of the PSMF
  • Registration of the PSMF
  • Regulatory requirements and accessibility of the PSMF
  • Responsibilities of the marketing authorisation holder, updates and the EU QPPV

The content of the PSMF

  • The PSMF template
  • The level of detail required by the PSMF
  • Preparation of the annexes
  • The PSMF log book

The sections of the PSMF

  • The EU QPPV
  • Sources of safety data
  • IT and databases
  • Regulatory timeline compliance
  • The PSMF processes
  • The PSMF and audits
  • The company quality system and the PSMF

The annex requirements for the PSMF

  • The company product list
  • The EU QPPV list of delegated tasks
  • The list of SOPs and procedures
  • List of delegated activities to third-party partners
  • A list of completed audits and schedules
  • A list of performance indicators for the PSMF section
  • The roles and responsibilities of the EU QPPV
  • Master file number and version changes (audit trail)

The PSMF and inspections

  • The PSMF and inspection findings
  • Regulatory authority requests to view the PSMF
  • Transfer of responsibility for a pharmacovigilance system to the QPPV
  • Notifying the QPPV of changes to the PSMF
  • PSMF responsibilities with shared marketing authorisation holders
  • Change control, logbook, versions and archiving
  • Audit trails and the PSMF
  • The PSMF post-inspection

Final discussion session

Speakers:

Graeme Ladds

Director

PharSafer Associates Ltd.

Graeme Ladds, Director of PharSafer, has over 30 years' experience working in the pharmaceutical industry. Having started his career at Ashbourne Pharmaceuticals in 1989 as Head of Drug Safety & Medical Information, he went on to become Head of Global Pharmacovigilance at Shire Pharmaceuticals. He then set up his consultancy and specialist CRO company, PharSafer Associates Ltd, where he has been involved in establishing pharmacovigilance in companies, performing audits across Europe and the USA, SOP writing, acting as QP for companies, and helping with regulatory inspections.

For more information about this training visit https://www.researchandmarkets.com/r/r6uqb1

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

U.S. Countertop Market Intelligence Report 2025-2030: Emerging Trend Reveals that Bold Patterns and Sintered Stones Shine - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "U.S. Countertop Market Research Report 2025-2030" has been added to ResearchAndMarkets.com's offering. The U.S. countertop market, valued at USD 28.65 billion in 2024, is projected to reach USD 32.44 billion by 2030, growing at a CAGR of 2.09%. This growth is fueled by the burgeoning interest in bold countertop patterns, sintered stone, high-performance porcelain, and the demand for smart countertops. An uptick in the use of ultra-compact and lightweight materials,...

CAR T-Cell Therapy for the Multiple Myeloma Market, 2025-2035: Extensive Data on Products, End Users, Regions and Companies - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "CAR T-Cell Therapy for Multiple Myeloma Market - A Global and Regional Analysis: Focus on Product, End User, and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. The chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking treatment modality, offering new hope for patients with relapsed or refractory multiple myeloma (RRMM). Building upon traditional treatments such as autologous stem cell transpl...

Fallopian Tube Cancer Market Analysis and Global Business Opportunities, 2025-2035 - Targeted Therapies Transform the Fallopian Tube Cancer Treatment Landscape - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Fallopian Tube Cancer Market - A Global and Regional Analysis: Focus on Type, Treatment Type, End User, and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. The global fallopian tube cancer market is being driven by several key factors. Rising awareness and early screening initiatives, supported by public health campaigns and improved diagnostic imaging technologies, are enabling earlier detection of gynaecologic cance...
Back to Newsroom